Biotech Business – August 26, 2026
Bio-Works Technologies has signed a new US customer, a major American biotech company, as a collaboration partner in the development of a new drug. The order is valued at SEK 2.8 million.
Collaboration – August 26, 2026
Finnish medtech company Koite Health has entered a research collaboration with Associated Brånemark Osseointegration Centers (ABOC), the global implantology network built on Professor Per-Ingvar Brånemark’s osseointegration research, to study how at-home antibacterial care can be integrated into structured preventive protocols for dental implant patients.
In a new job – August 25, 2026
ALK-Abelló has appointed Jacob Glenting as Executive Vice President and head of Global R&D, effective 1 September.
Pharma Business – August 25, 2026
The US FDA has proposed reclassifying blue light cystoscopy (BLC) systems used with Photocure’s imaging agent Cysview for bladder cancer detection from Class III to Class II, a move the Norwegian medtech company says will support wider adoption of the technology in US hospitals.
New Market – August 24, 2026
Norwegian microbiome diagnostics company Genetic Analysis has placed its GA-map Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney – the company’s first placement in Australia and a new milestone in its international expansion.
Biotech Business – August 24, 2026
Nykode Therapeutics has been granted a new US patent covering its individualized neoantigen cancer vaccine VB10.NEO and related modular vaccine designs, strengthening the company’s intellectual property position as the neoantigen vaccine field gains momentum.
Clinical Trials – August 24, 2026
Elicera Therapeutics has reported continued strong results from its Phase I/IIa CARMA study of ELC-301 in relapsed or refractory B-cell lymphoma, with an overall response rate of 91 percent and disease control in all evaluable patients.
Clinical Trials – August 20, 2026
Merck and Moderna have reported positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene in combination with Keytruda in patients with completely resected, high-risk melanoma.
Clinical Trials – August 19, 2026
The company has received regulatory approval from the European Medicines Agency, to conduct PP-CT04, a two-part, randomized, double-blind, placebo-controlled, parallel-group, 12‑week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants.
Clinical Trials – August 17, 2026
The first clinical site has been activated in the company’s global Phase IIb EPIMODE trial evaluating lead drug candidate CS1 in pulmonary arterial hypertension (PAH).
Clinical Trials – August 4, 2026
Nykode Therapeutics has presented comprehensive preclinical and clinical data on VB10.NEO, its individualized neoantigen therapy (INT), at the Neoantigen Summit in Amsterdam, reinforcing the program as a differentiated platform ready for strategic partnership.
Clinical Trials – July 14, 2026
Evaxion has presented new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.
Almirall Nordic
This is an opportunity to combine strong execution, stakeholder engagement, and health-economic messaging in a highly impactful field role.
PharmaRelations
We are looking for a passionate commercially minded Senior Recruitment Manager who wants to make a real impact by attracting exceptional talent, strengthening client partnerships and helping us on our mission to grow individuals and companies in Life Science.
PharmaRelations
Lead strategy, consulting and business growth across the Nordic Life Science market.
PharmaRelations
We are looking for a supply chain professional with SAP experience who can support a SAP S/4HANA transition project while helping ensure continuity across selected logistics processes.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs. You will work with several clients in parallel giving you great variation in your daily work. You may also have the opportunity to mentor and support other PV consultants within PharmaRelations.
Thea Nordic
PharmaRelations is now looking for a Head of Clinical Operations who wants to continue to build up and develop our business in Denmark and South of Sweden (Öresundsregionen).
In a new job – August 18, 2026
The Board of Directors of BICO Group AB has announced the appointment of Anders Fogelberg, currently Chief Commercial Officer, as President and CEO, effective September 1, 2026.
In a new job – August 18, 2026
Eva Lindskog succeeds Lone Carlbom, who will return to an operational role after serving as the company’s CEO.
In a new job – August 18, 2026
Elicera Therapeutics appoints Johan Liwing as new CEO effective September 1, 2026.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Careers article – June 14, 2026
Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.
Career choice – June 14, 2026
Lionel Leck’s research focuses on pediatric cancer, particularly neuroblastoma – one of the most commonly diagnosed childhood cancers with a poor prognosis.
Europe – July 13, 2026
Spanish biochemist and molecular biologist Salvador Aznar Benitah’s research focuses on how adult stem cells function in normal conditions, aging, and cancer, with particular interest in epigenetics, circadian rhythms, and the mechanisms that allow certain cancer cells to initiate metastasis.
Profiles in Science – April 22, 2026
It’s one thing to “do” physics – but it’s another to explain its fundamentals to others, and the role that physics and other sciences play in their lives.
Profiles in Science – March 23, 2026
Dr. Joanna Rorbach, principal researcher at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, has been awarded the prestigious Göran Gustafsson Prize by the Royal Swedish Academy of Sciences (Kungliga Vetenskapsakademien).
Pharma Business – August 24, 2026
Bavarian Nordic has upgraded its financial guidance for 2026, now expecting total revenue of approximately DKK 5,700 million and an EBITDA margin of around 30 percent, on the back of continued strength in its Public Preparedness business. The Danish vaccine maker is also launching a new share buyback programme of up to DKK 750 million.
Biotech Business – August 21, 2026
The company has announced confidential submission of draft registration statement to the SEC to allow for a potential listing of ADSs in the United States.
Financing – August 20, 2026
Pixelgen Technologies has closed an oversubscribed USD 15.5 million Series B financing to accelerate global commercialization of its Proxiome Kit and expand the company’s presence in key markets.
MedTech Business – August 21, 2026
The FDA has granted Premarket Approval (PMA) for RefluxStop, the company’s implant-based treatment for gastroesophageal reflux disease (GERD).
MedTech Business – August 12, 2026
The U.S. Department of Veterans Affairs (VA) Strategic Acquisition Center has awarded a five-year national Non-Expendable Equipment (NX EQ) contract for quantitative neuromuscular monitoring to TrillaMed, LLC, the authorized U.S. federal distributor of the Senzime TetraGraph system.
MedTech Business – August 11, 2026
XVIVO’s heart preservation technology, XVIVO Heart Assist Transport system, has received CE certificates, making it available to any heart transplant center throughout Europe.
Agreement – August 21, 2026
Swedish biotech company Akiram Therapeutics has signed an agreement with ITM Isotope Technologies Munich to supply non-carrier-added lutetium-177 for the clinical development of AKIR001.
Biotech Business – August 19, 2026
BioArctic and Mesenkia Therapeutics have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge.
Biotech article – August 12, 2026
Sweden has retained its position as the European Union’s most innovative member state, while Denmark ranks second, according to the European Commission’s European Innovation Scoreboard 2026.
Collaboration – August 19, 2026
The Lundbeck Foundation has awarded DKK 78 million to a pan-Nordic centre that will focus on research into the glymphatic system.
Iceland – August 17, 2026
From August 18-24, 2026, patients, physicians, caregivers, and supporters from around the world will embark on a six-day cycling expedition across Iceland with the purpose of accelerating research into multiple myeloma.
Collaboration – August 17, 2026
The network has researchers from Iceland, Norway, Sweden, Finland and Denmark. “It is absolutely crucial that we work together in the Nordic Region, because this is a rapidly developing scientific field, and when we join forces across the Nordic countries, we can compare ourselves with larger countries such as France, Germany and Italy. The Nordic […]
This site uses cookies
